For example, MAPT mRNA-targeting ASOs in a mouse model of tauopathy resulted in a 50% reduction of endogenous intracellular tau, reduced cell-to-cell spread of oligomerized tau, markedly reduced neuronal and cognitive impairments and was not associated with adverse consequences15. The gene discussed is MAPT; the disease is tauopathy.